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To the Editor: It has been estimated that globally about 38.6 million 
people were infected with HIV by 2005,1 with about 5 million of them 
living in South Africa (SA). The World Health Organization estimated 
that 4.7 million people living in sub-Saharan Africa urgently needed 
antiretroviral therapy (ART). In that year SA implemented prescribed 
minimum benefits (PMBs) for HIV/AIDS in the private health care 
sector.2 Despite the increased availability and affordability of ART 
in SA, only 60 000 people were receiving ART through medical aid 
schemes by mid-2005.3
Antiretrovirals (ARVs) have transformed HIV/AIDS into a chronic 
disorder that can be managed effectively. The right of all HIV-
infected adults and children to receive standard care is endorsed by 
the SA HIV Clinicians Society (SAHIVCS),4 with ART guidelines 
recommending different combinations. The rapid approval of new 
drugs resulted in an increased risk of prescribing errors, dispensing of 
incorrect dosages/dose frequencies, and incorrect reporting of drugs 
by the patient to the prescribers,5 all leading to treatment failure.
Drug-drug interactions (DDIs) are an under-recognised 
consequence of medication prescription errors, resulting in 
significant health care costs.6 Since DDIs determine positive and 
negative consequences of treatment for HIV-infected patients, 
recommendations to avoid some drug combinations and to adjust 
dosages of some co-administered drugs were formulated by both the 
SAHIVCS4 and the Department of Health.7 The private health care 
environment recommends the Aid for AIDS ART guidelines, which 
are similar to those of the SAHIVCS (Table I).
We investigated the prevalence of prescriptions with potential 
DDIs between ARVs from general practitioners (GPs) and specialists 
(SPs) for patients in different age groups in the private health care 
sector, and evaluated the prescribed daily dosages (PDDs).
Methods
A non-experimental, retrospective, quantitative study was performed 
on data from a South African Pharmacy Benefit Management (PBM) 
company from 1 January 2005 to 31 December 2007. ARV drug 
names were classified according to the pharmacological groups in 
the Monthly Index of Medical Specialities (MIMS) and the Regulations 
to the Medicine and Related Substances Act (Act 101 of 1965). 
Prescribers of ARVs were divided into GPs and SPs.
Potential DDIs between ARVs were identified and classified 
as clinically major, moderate or minor.9 DDIs were assigned 
documentation levels of established, probable or suspected with 
significance ratings of 1, 2, 3, 4 and 5. We focused only on DDIs with 
clinical significance rating of 2, this rating being the most common 
between ARVs. 
We evaluated potential DDIs between ARVs using PDDs. It is 
important that the PDD be related to the diagnosis made for the 
prescribed medication. The reference guides used to evaluate PDDs 
were according to the recommended ARV dosing.4,7,8
Basic descriptive statistics, i.e. frequencies, the arithmetical mean 
(average), standard deviations and effect sizes (Cohen’s d) were 
used to characterise the study sample, and were calculated using the 
computer software Statistical Analysis System (SAS) for Windows 
9.1. The age groups used were as follows: group 1 – 0≤12 years, group 
2 – >12≤19 years, group 3 – >19≤45 years, group 4 – >45≤59 years, 
and group 5 – >59 years.
Confidentiality of information was maintained, as no patient, 
medical practice, pharmacy or medical scheme could be identified. 
Permission to conduct the study was granted by the PBM company, 
and approval was obtained from the research and ethics committees 
of North-West University, Potchefstroom campus, (ethical number 
07M01) and Walter Sisulu University, Mthatha campus. 
Results
The study was performed on 49 995, 81 096 and 88 988 ARV 
prescriptions prescribed to 7 664, 10 162 and 10 061 HIV patients 
in 2005, 2006 and 2007, respectively. ARV prescriptions represented 
0.59% (N=49 995), 0.90% (N= 81 096); and 1.11% (N= 88 988) of the 
claims for the 3 years. 
In the 3 years, GPs prescribed more ARV prescriptions than SPs, 
and these increased from 2005 to 2007. The highest proportion of 
prescriptions was for three ARV items, followed by two ARV items. 
No practically significant differences were found between the average 
numbers of ARV medicine items per prescription (d<0.8) claimed per 
year for the different years.
ARV prescriptions from GPs with potential DDIs and incorrect 
PDDs increased from 12.33% in 2005 to 24.26% in 2007; those from 
SPs increased from 15.46% in 2005 to 35.30% in 2006 and decreased 
to 33.16% in 2007. The highest numbers of incorrect PDDs with 
DDIs were identified in ARV combinations of lopinavir/ritonavir 
1 066.4 mg/264 mg with efavirenz 600 mg, and lopinavir/ritonavir 
1 066.4 mg/264 mg with nevirapine 400 mg, followed by indinavir 
1 600 mg with ritonavir 800 mg, ritonavir 600 mg with efavirenz 600 
mg, and saquinavir 800 mg with efavirenz 800 mg, for both GPs and 
SPs. The highest number of prescriptions were prescribed by GPs to 
patients in the age group >19≤45 years, followed by the age group 
>45≤59 years.
Discussion
We aimed to determine the prevalence of ARV prescriptions with 
potential DDIs and to evaluate their PDDs with specific reference 
to prescriber and age group. DDIs are of particular concern in HIV 
patients receiving highly active antiretroviral therapy. Although 
combination ARV treatment is potent and effective for HIV infection, 
ARVs frequently interact among themselves as many are metabolised 
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through the same CYP450 system.10 These interactions support the 
recommendations to avoid some combinations of drugs and to adjust 
the dosage of other drugs when co-administered.
The ARV regimens most identified with incorrect PDDs were 
between lopinavir/ritonavir (PI) prescribed at PDDs 1 066.4 mg/264 
mg, 4 500 mg/3 999 mg and 1 599.6 mg/264 mg with efavirenz 
(non-nucleoside reverse transcriptase inhibitor) (NNRTI), then 
the same with nevirapine. These were followed by indinavir (PI) 
with ritonavir (PI), saquinavir (PI) with efavirenz, and saquinavir 
with ritonavir. All these combinations were prescribed to patients 
aged >19≤45 years. The standard adult dose for lopinavir/ritonavir 
is 400 mg/100 mg twice daily or 800 mg/200 mg once daily.7 A 
limitation of this study was that information about whether patients 
were HIV naïve or experienced was not available. Once-daily 
dosing for lopinavir/ritonavir is only recommended for treatment-
naïve patients, and not for patients receiving efavirenz, nevirapine 
or nelfinavir. When lopinavir/ritonavir is given with efavirenz 
or nevirapine, the recommended dose for treatment-experienced 
patients is 600 mg/150 mg twice daily with food.7,8
Furthermore, the results revealed that GPs prescribed lopinavir/
ritonavir for patients in the age group 0≤12 years. Another limitation 
of this study was that the weights for children were not available 
and it was not clear to which weight and age categories of patients 
this co-formulation was prescribed. The safety, efficacy and 
pharmacokinetic profiles of lopinavir/ritonavir in children under the 
age of 6 months have not been established. The paediatric dose for 
lopinavir/ritonavir as recommended in the SA ART guidelines is 12 
mg lopinavir/kg twice daily for children weighing <15 kg and 10 mg 
lopinavir/kg for children ≥15 kg. In this case lopinavir/ritonavir was 
prescribed in a higher PDD, considering one capsule of lopinavir/
ritonavir to be 133.3 mg/33.3 mg, with the maximum dose not 
exceeding 399.9 mg/99.9 mg.7 If given in higher PDDs the patient 
may therefore experience side-effects such as diarrhoea, nausea, 
vomiting, hyperlipidaemia and glucose intolerance.7
We observed that ritonavir was given with other PIs in PDDs 
of 3 000 mg, 1 200 mg, 800 mg and 600 mg. The recommended 
dosages of 100 mg capsules or 600 mg/7.5 ml solutions in adults 
are 600 mg every 12 hours (when ritonavir is used as sole PI). As a 
pharmacokinetic booster for other PIs, the recommended dosage is 
100 - 400 mg per day in two divided doses.7 Boosted PI regimens that 
utilise a low dose of ritonavir (100 - 200 mg) appear to offer the best 
balance of efficacy and tolerability.
Limitations
Limitations of this study include non-availability of patient clinical 
data to do in-depth clinical evaluation of the potential DDIs and 
PDDs. The extent to which potential DDIs actually occurred 
could therefore not be determined. Information on HIV-naïve 
or experienced patients, CD4 values and viral loads were not 
available from the database. The clinical relevance of the identified 
potential DDIs was evaluated according to criteria in the literature. 
Information about the pharmacists who dispensed the prescriptions 
was not available. Pharmacists in collaboration with the prescriber 
could have detected and corrected prescriptions with potential DDIs 
and incorrect doses, this being one of the primary responsibilities of 
specific pharmacists. However, the results emphasised the possibility 
of DDIs that could have caused severe problems. A further limitation 
of the study was that no differentiation could be made between 
the prescription patterns of dispensing doctors versus pharmacy-
dispensed prescriptions.
Conclusion
Our results emphasise the important role of prescribers and 
pharmacists in ensuring the appropriate use of ARVs. The importance 
of educating prescribers and dispensers by medical schemes or PBM 
companies in the private health care sector is also emphasised.
We gratefully acknowledge the managers of PBM who provided the data 
for the research project. 
References
  1.    UNAIDS/WHO. AIDS epidemic update. Global Summary. December 2007. Geneva, Switzerland. www.
uunaids.org (accessed 14 June 2008). 
  2.    Erasmus S. Medical schemes in South Africa. HIV becomes prescribed minimum benefit. http://www.
health24.com/medical/condition_centres/777-792-2002-2007,30583.asp (accessed 19 July 2007).
  3.    Johnson L. Estimated numbers of patients on antiretroviral treatment in the South African private 
health sector. AIDS Analysis Africa Online, January/February 2006 issue. http://www.redribbon.co.za/
documents_v2/aids_ana/AAAO_Jan_Feb2006.pdf (accessed 29 March 2011).
  4.    South African HIV Clinicians Society Clinical Guidelines. Antiretroviral therapy in adults. http://www.
hst.org.za/uploads/files/clincalguide_adults.pdf (accessed 25 January 2009).
  5.    Arshad S, Rothberg M, Rastegar DA, et al. Survey of physician knowledge regarding antiretroviral 
medications in hospitalized HIV-infected patients. Journal of the International AIDS Society 
2009;12:1.
  6.    Heelon M, Skiest D, Tereso G, et al. Effect of a clinical pharmacist’s interventions on duration of 
antiretroviral-related errors in hospitalized patients. Am J Health Syst Pharm 2007;64:2064-2068. 
  7.    National Department of Health South Africa. 2005. ARV drug choices for children. In:  Guidelines for 
the Management of HIV-infected Children. Jacana Media: Pinetown Printers. 
  8.    Aid for Aids. Selecting Drug Combinations. AfA Clinical Guidelines. 2005. http://aidforaids.co.za/
ex_MEDSCHEME_VS07/Documents/AFA/Guidelines_book_Final.pdf (accessed 25 May 2008). 
  9.    Tatro DS. Drug Interaction Facts. St Louis: Facts and Comparisons, 2005: 1-1699.  
10.    De Maat MM, Ekhart GC, Huitema AD, et al. Drug interactions between antiretroviral drugs and 
comedicated agents. Clin Pharmacokinet 2003;42:223-282.
Accepted 8 February 2011.
Table I. Recommended drug combinations in the private sector8
                                    Dose
PI-naïve patient PI-experienced patient
PIs Nevirapine Efavirenz Nevirapine Efavirenz
Atazanavir/ritonavir Not recommended 400 mg/100 mg once a day Not recommended 400 mg/100 mg
Darunavir/ritonavir SD SD SD SD
Lopinavir/ritonavir SD SD 600 mg/150 mg twice daily 600 mg/150 mg twice daily
Saquinavir/ritonavir SD SD SD SD
PI = protease inhibitor; SD = standard dose.
